 |
 |
 |
| |
PARA OS DIABÉTICOS DEPENDENTES DE INSULINA
De: PR Newswire Brasil
Para: THERESA CATHARINA DE GÓES CAMPOS
Assunto: TAXUS(TM) Stent System Shows Superior
Outcomes in Insulin-Dependent Diabetic Patients
17 de outubro de 2005 15:57 HORALOCAL
TAXUS(TM) Stent System Shows Superior Outcomes
in Insulin-Dependent Diabetic Patients
First-ever clinically significant outcome for
insulin-dependent diabetic patients
PARIS, Oct. 17 /PRNewswire/ -- A review of
subgroup data from a randomized, controlled
drug-eluting stent (DES) clinical trial, TAXUS
IV(1), found that the TAXUS(TM)
paclitaxel-eluting stent system has
substantially improved clinical outcomes in
insulin-dependent patients.
With bare-metal stents, insulin-dependent
diabetic patients have a 42 percent greater risk
of target lesion revascularization (TLR), a
measure of reintervention as a result of
reclogging of the artery following stenting,
compared to non-diabetic patients.(2) In the
TAXUS IV study, the nine-month TLR rate was 5.9
percent for the subgroup of insulin-dependent
diabetic patients. A similar study, SIRIUS(3),
showed a 13.2 percent TLR rate for the Cypher(R)
stent.
The excellent results of the TAXUS stent system
in insulin-dependent diabetics are consistent
across clinical trials. A new meta-analysis(4)
that contains data from four major randomized,
controlled clinical trials with follow-up out to
three years shows that the TAXUS stent system
has the first-ever clinically significant
outcome for insulin-dependent diabetic patients.
"The difference between patient outcomes in
insulin-dependent diabetics is clear: the TAXUS
stent provides a superior treatment option,"
said Dr. Keith Dawkins of the Southampton
University Hospital, Southampton, UK. "Paclitaxel
-- the drug used on the TAXUS stent -- appears
to have a novel mechanism of action that is a
benefit to patients with insulin-requiring
diabetes. The 'Limus' family of drugs --
including sirolimus -- may not work as
effectively in these types of patients."
Insulin-dependent diabetic patients are at a
very high risk for coronary artery disease, and
they are difficult to treat using stents due to
high restenosis rates. This high-risk group is
therefore an important benchmark for assessing
the efficacy of drug-eluting stents.
Heart disease will contribute to the cause of
death in more than 50 percent of the diabetic
population(5) in industrialized countries.
Because of the strong relationship between
patients with diabetes and heart disease, the
interest in DES clinical trials with diabetics
is very high. The insulin-dependent patient
population is estimated to be approximately 15
million worldwide.(6)
Boston Scientific is a worldwide developer,
manufacturer and marketer of medical devices
whose products are used in a broad range of
interventional medical specialties. For more
information, please visit:
www.bostonscientific.com .
This press release contains forward-looking
statements. Boston Scientific wishes to caution
the reader of this press release that actual
results may differ from those discussed in the
forward-looking statements and may be adversely
affected by, among other things, risks
associated with new product development and
commercialization, clinical trials, intellectual
property, regulatory approvals, competitive
offerings, Boston Scientific's overall business
strategy, and other factors described in Boston
Scientific's filings with the Securities and
Exchange Commission.
References
1. Stone GW, Ellis SG, Cox DA et al. Circulation
2004;109:1942-7.
TAXUS IV study sponsored by Boston Scientific
Corp.
2. Abizaid A, Kornowski R, Mintz GS et al.
Journal of the American
College of Cardiology 1998;32:584-9
3. Moses JW, Leon MB, Popma JJ et al. N Engl J
Med
2003;349:1315-23.
SIRIUS Trial sponsored by Cordis Corp.
4. Trials included in TAXUS(TM) Meta Analysis:
TAXUS II, TAXUS IV,
TAXUS V, TAXUS VI. Boston Scientific: Data on
file.
5.-6. World Health Organization
http://www.who.int/mediacentre/factsheets/fs138/en/index.html
Trademarks
Cypher(R) stent is a trademark of Cordis Corp.
TAXUS(TM) stent is a trademark of Boston
Scientific
SOURCE Boston Scientific Corporation
10/17/2005
CONTACT: Maren Koban, BSC press office,
+44-(0)-20-7973-4497,
mkoban@hillandknowlton.com, or Natacha
Gassenbach, Media Relations -
Boston Scientific Corporation, +33-6-08-97-70-36
(mobile)
Web site: http://www.bostonscientific.com
BNED: NG
FONTE: PR NEWSWIRE LATIN AMERICA
CORAL GABLES - MIAMI-US
CONTATOS: USA-MARY D'LEON
BRASIL-NÉLIA GARCIA
TELS: USA:1-305-507-2550/BRASIL:55-21-2132-8461
FAXES: USA:1-305-461-8670/BRASIL:55-21-2132-8469
E-MAILS: nelia_garcia@prnewswire.com.br
mary_dleon@prnewswire.com
PALAVRA-CHAVE: RJ
PALAVRA-CHAVE/RAMO DE ATIVIDADE: MEDICINA
PALAVRA-CHAVE/EMPRESA: BOSTON SCIENTIFIC
CORPORATION
O texto acima, distribuído pela PR Newswire
Brasil, é de inteira responsabilidade de seu
cliente. A utilização deste material não implica
em custo.
|
|
|
|
